The new Italian pharmaceutical group announces 456 layoffs (out of 1,626 employees). Zago (Filctem Cgil): "The industrial project cannot do without all those valid skills that have determined the positive results of the company so far"
National strike and garrison today (Thursday 28 September) in Milan by the workers of the pharmaceutical company Alfasigma. The appointment is under the headquarters of Assolombarda, on the occasion of the resumption of negotiations for the 456 layoffs (out of 1,626 employees). The decision came on 6 September last, when the new industrial plan was communicated, which precisely provides for the need for a reorganization based on redundancies.
"The objective of the negotiation is to modify the serious organizational decisions taken by the company, which heavily affect many workers". To say it is Aldo Zago, of the Pharmaceutical Chemical Department of the national Filctem Cgil: "The industrial project of this new pharmaceutical group cannot do without all those valid skills that have determined, up to now, the positive results of the company". The cuts, in particular, should affect 274 scientific computer scientists and 182 administrative employees (of which 138 in the former Sigma Tau headquarters in Pomezia, in Rome) divided into all company offices.
Alfasigma brings together in a single company some of the major national pharmaceutical groups, with wholly Italian capital (75 percent of the company belongs to the Golinelli family). It is currently the third company in the sector, its turnover exceeds one billion euros. It is also a newborn company: in fact, it was formed on 1st August through the merger of Alfa Wassermann, Biofutura Pharma and Sigma-Tau Industrie Farmaceutiche Riunite. The production sites are in Alanno (Pescara), Sermoneta (Latina) and Pomezia (Rome), the administrative office is in Bologna and the legal office in Milan (which also coordinates the scientific information activity of the drug).
The reasons given by the company, we read in a parliamentary question by Pd deputy Marco Miccoli, were: “the critical dimension in financial terms and in terms of the production structure in order to be able to act in the complex global competitive context; the slight decrease in the pharmaceutical market in the retail channel, where the turnover is concentrated alphasigma; national pharmaceutical spending 30 percent lower than in other large European countries; the containment of expenditure in the sector, as for example in the revision of the formulary which took place in 2015; the duplication of some professional figures which was determined by the definitive maxi-merger”.
Related news: Alfasigma layoffs. Questions to the Chambers
ALFASIGMA, dismissal procedure started for 456 workers, 274 scientific representatives
